Claudia Haberland

Berlin, BE, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Elinzanetant for the Treatment of Menopausal Hot Flashes: A Plain Language Review of the OASIS-1-4 Clinical Trial Results.

Elinzanetant for the Treatment of Menopausal Hot Flashes: A Plain Language Review of the OASIS-1-4 Clinical Trial Results.

Journal: Women's health (London, England)

Published: July 14, 2026

Consistency of efficacy and safety of elinzanetant for vasomotor symptoms and sleep disturbance associated with menopause across different populations: a review of the OASIS clinical trial program.

Consistency of efficacy and safety of elinzanetant for vasomotor symptoms and sleep disturbance associated with menopause across different populations: a review of the OASIS clinical trial program.

Journal: Maturitas

Published: April 15, 2026

Efficacy and Safety of Vilaprisan in the Treatment of Uterine Fibroids: Data from ASTEROID 5, a Phase 3 Multicenter Randomized Controlled Trial.

Efficacy and Safety of Vilaprisan in the Treatment of Uterine Fibroids: Data from ASTEROID 5, a Phase 3 Multicenter Randomized Controlled Trial.

Journal: Journal of clinical medicine

Published: January 15, 2026

Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: A Phase 3 Randomized Clinical Trial.

Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: A Phase 3 Randomized Clinical Trial.

Journal: JAMA internal medicine

Published: September 08, 2025

Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer.

Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer.

Journal: The New England journal of medicine

Published: June 02, 2025

Exit Interviews Examining Changes to Mood and Work/Productivity Impacts Related to Vasomotor Symptoms: Perspectives of Postmenopausal Women Receiving Elinzanetant in Phase III Clinical Trials.

Exit Interviews Examining Changes to Mood and Work/Productivity Impacts Related to Vasomotor Symptoms: Perspectives of Postmenopausal Women Receiving Elinzanetant in Phase III Clinical Trials.

Journal: The patient

Published: May 29, 2025

Psychometric evaluation of the HFDD, PROMIS SD SF 8b, and MENQOL questionnaire in women experiencing vasomotor symptoms associated with menopause.

Psychometric evaluation of the HFDD, PROMIS SD SF 8b, and MENQOL questionnaire in women experiencing vasomotor symptoms associated with menopause.

Journal: Journal of patient-reported outcomes

Published: January 13, 2025

Qualitative exploration of women's experiences of vasomotor symptoms to support the content validity of patient-reported outcomes.

Qualitative exploration of women's experiences of vasomotor symptoms to support the content validity of patient-reported outcomes.

Journal: Journal of patient-reported outcomes

Published: October 08, 2024

Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: OASIS 1 and 2 Randomized Clinical Trials.

Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: OASIS 1 and 2 Randomized Clinical Trials.

Journal: JAMA

Published: August 22, 2024

Psychometric validation of the severity of chronic cough diary, leicester cough questionnaire, and a cough severity visual analogue scale in patients with refractory chronic cough.

Psychometric validation of the severity of chronic cough diary, leicester cough questionnaire, and a cough severity visual analogue scale in patients with refractory chronic cough.

Journal: Journal of patient-reported outcomes

Published: August 19, 2024

Design of OASIS 1 and 2: phase 3 clinical trials assessing the efficacy and safety of elinzanetant for the treatment of vasomotor symptoms associated with menopause.

Design of OASIS 1 and 2: phase 3 clinical trials assessing the efficacy and safety of elinzanetant for the treatment of vasomotor symptoms associated with menopause.

Journal: Menopause (New York, N.Y.)

Published: April 02, 2024

Comparative performance of PROMIS Sleep Disturbance computerized adaptive testing algorithms and static short form in postmenopausal women.

Comparative performance of PROMIS Sleep Disturbance computerized adaptive testing algorithms and static short form in postmenopausal women.

Journal: Journal of patient-reported outcomes

Published: March 25, 2024

Showing 1-12 of 19

Last Updated: 09/26/2026